大华继显:AI创新及国策推动内地互联网医疗领域 看好阿里健康(00241)及平安好医生(01833)

智通财经
Feb 16

智通财经APP获悉,大华继显发布研报称,内地互联网医疗领域正进入新阶段,推动力包括科技巨头加快AI创新以及国策支持,例如北京推出的线上初诊试点计划。虽然面临盈利能力挑战,但龙头企业正利用AI生态系统及创新策略,部署长远持续增长。



选股方面,该行看好阿里健康(00241),维持“买入”评级及目标价7.8港元;预期在创新药及医疗健康产品增长动能持续、与阿里巴巴-W(09988)协同效应深化,以及AI应用日益普及的推动下,阿里健康2026至2028财年的收入及经调整净利润年均复合增长率将达13%及24%。



另外,该行亦看好平安好医生(01833),维持“买入”评级,目标价20港元;预期在与中国平安(02318)协同效应深化,及AI持续赋能的推动下,公司2025至2027年的收入及经调整净利润年均复合增长率将达16%及56%。



同时,该行对内地医疗板块维持“增持”评级,偏好领先的创新药企和合约研究、开发及生产组织(CRDMO),同时看好能够有效运用真实世界数据以优化AI算法,以提升服务质量的互联网医疗企业。首选股份包括百济神州(06160)、信达生物(01801)、翰森制药(03692)、中国生物制药(01177)、和黄医药(00013)、药明生物(02269)、药明康德(02359)及阿里健康。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10